History
  • No items yet
midpage
Vivera Pharmaceuticals v. GD Laboratory Consulting CA4/3
G063498
| Cal. Ct. App. | Feb 21, 2025
Read the full case

Background

  • Vivera Pharmaceuticals, Inc., GD Laboratory Consulting, LLC, and others formed a joint COVID-19 testing venture, Focal Point Laboratories, which ceased operations in June 2021.
  • After business dissolution, Vivera's CEO withdrew $600,000 from Focal Point's account, prompting Vivera to sue for accounting, and Focal Point to counter-sue; the cases were consolidated.
  • A court-appointed receiver was established to control Focal Point’s assets as litigation proceeded.
  • Blaine Holding & Development, LLC had previously secured a $400,000 judgment against Vivera in a separate matter and filed a judgment lien in this case.
  • The parties reached a settlement where Vivera received a release of claims but no money, and the settlement required court approval due to the outstanding lien.
  • The court approved the settlement, finding no abuse in its structure or intent to evade Blaine’s lien, and Blaine appealed.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Was the trial court right to approve the settlement despite Blaine's lien? Settlement was fair; Vivera received only a release, not money. Settlement evaded valid lien; Vivera benefitted unfairly. Court approved settlement; no abuse of discretion found.
Should review be de novo or for abuse of discretion? Abuse of discretion applies as court balanced equities. De novo review correct due to statutory language. Abuse of discretion standard is proper.
Did the statutory lien attach to Vivera’s cause of action or any judgment proceeds? Lien only attaches to proceeds Vivera receives in litigation. Lien attaches to any money Vivera could receive, per statute. Lien did not attach, as Vivera received no money/property.
Do precedents (such as Abatti and Oldham) compel reversal? Distinct facts—here, Vivera received release only, not cash. Case law shows court must not approve settlements evading liens. Court distinguished those cases; facts not analogous here.

Key Cases Cited

  • Pangborn Plumbing Corp. v. Carruthers & Skiffington, 97 Cal.App.4th 1039 (Cal. Ct. App. 2002) (standard for abuse of discretion in settlement approval)
  • Oldham v. California Capital Fund, Inc., 109 Cal.App.4th 421 (Cal. Ct. App. 2003) (reversal required where court lacks information for settlement approval)
  • Abatti v. Eldridge, 112 Cal.App.3d 411 (Cal. Ct. App. 1980) (limitations on settlements affecting judgment creditors, later changed by statute)
Read the full case

Case Details

Case Name: Vivera Pharmaceuticals v. GD Laboratory Consulting CA4/3
Court Name: California Court of Appeal
Date Published: Feb 21, 2025
Docket Number: G063498
Court Abbreviation: Cal. Ct. App.